It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NVSEF’s FA Score shows that 2 FA rating(s) are green whileSNY’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NVSEF’s TA Score shows that 4 TA indicator(s) are bullish while SNY’s TA Score has 6 bullish TA indicator(s).
NVSEF (@Pharmaceuticals: Major) experienced а -1.33% price change this week, while SNY (@Pharmaceuticals: Major) price change was +1.79% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -2.43%. For the same industry, the average monthly price growth was -3.05%, and the average quarterly price growth was -1.91%.
SNY is expected to report earnings on Jan 30, 2025.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
NVSEF | SNY | NVSEF / SNY | |
Capitalization | 217B | 123B | 176% |
EBITDA | 17.8B | 12.6B | 141% |
Gain YTD | -2.566 | 2.583 | -99% |
P/E Ratio | 29.50 | 20.80 | 142% |
Revenue | 53.1B | 46.4B | 114% |
Total Cash | 11.2B | 8.98B | 125% |
Total Debt | 28.3B | 18.4B | 154% |
NVSEF | SNY | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 99 | 69 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 12 Undervalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 59 | 50 | |
SMR RATING 1..100 | 22 | 80 | |
PRICE GROWTH RATING 1..100 | 74 | 62 | |
P/E GROWTH RATING 1..100 | 87 | 27 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SNY's Valuation (10) in the Pharmaceuticals Major industry is in the same range as NVSEF (12) in the null industry. This means that SNY’s stock grew similarly to NVSEF’s over the last 12 months.
SNY's Profit vs Risk Rating (50) in the Pharmaceuticals Major industry is in the same range as NVSEF (59) in the null industry. This means that SNY’s stock grew similarly to NVSEF’s over the last 12 months.
NVSEF's SMR Rating (22) in the null industry is somewhat better than the same rating for SNY (80) in the Pharmaceuticals Major industry. This means that NVSEF’s stock grew somewhat faster than SNY’s over the last 12 months.
SNY's Price Growth Rating (62) in the Pharmaceuticals Major industry is in the same range as NVSEF (74) in the null industry. This means that SNY’s stock grew similarly to NVSEF’s over the last 12 months.
SNY's P/E Growth Rating (27) in the Pharmaceuticals Major industry is somewhat better than the same rating for NVSEF (87) in the null industry. This means that SNY’s stock grew somewhat faster than NVSEF’s over the last 12 months.
NVSEF | SNY | |
---|---|---|
RSI ODDS (%) | 2 days ago71% | 2 days ago64% |
Stochastic ODDS (%) | 2 days ago46% | 2 days ago51% |
Momentum ODDS (%) | 2 days ago55% | 2 days ago52% |
MACD ODDS (%) | 2 days ago46% | 2 days ago47% |
TrendWeek ODDS (%) | 2 days ago49% | 2 days ago53% |
TrendMonth ODDS (%) | 2 days ago45% | 2 days ago50% |
Advances ODDS (%) | 22 days ago43% | 24 days ago53% |
Declines ODDS (%) | N/A | 3 days ago49% |
BollingerBands ODDS (%) | 2 days ago63% | 2 days ago58% |
Aroon ODDS (%) | 2 days ago45% | 2 days ago48% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
SJNK | 25.48 | -0.03 | -0.12% |
SPDR® Blmbg ST HY Bd ETF | |||
BAUG | 44.23 | -0.07 | -0.16% |
Innovator U.S. Equity Buffer ETF Aug | |||
MGOV | 19.99 | -0.04 | -0.20% |
First Trust Intermediate Gvt Opps ETF | |||
HIYS | 25.72 | -0.06 | -0.21% |
Invesco High Yield Select ETF | |||
EQAL | 49.82 | -0.46 | -0.91% |
Invesco Russell 1000 Equal Weight ETF |
A.I.dvisor tells us that NVSEF and SNYNF have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NVSEF and SNYNF's prices will move in lockstep.
Ticker / NAME | Correlation To NVSEF | 1D Price Change % | ||
---|---|---|---|---|
NVSEF | 100% | N/A | ||
SNYNF - NVSEF | 27% Poorly correlated | +7.45% | ||
SNY - NVSEF | 21% Poorly correlated | +6.65% | ||
NVS - NVSEF | 20% Poorly correlated | +1.36% | ||
KYKOF - NVSEF | 7% Poorly correlated | N/A | ||
GIKLY - NVSEF | 6% Poorly correlated | +2.19% | ||
More |
A.I.dvisor indicates that over the last year, SNY has been loosely correlated with SNYNF. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if SNY jumps, then SNYNF could also see price increases.